What Clarification Does WHO Seek from India Regarding 'Coldrif' Cough Syrup Exports?
Click to start listening
Synopsis
The WHO awaits crucial information from Indian authorities on the export of Coldrif cough syrup, which has been linked to tragic child fatalities. This inquiry raises significant health concerns about cough syrup safety in pediatric care, prompting urgent action from health agencies across the country.
Key Takeaways
- WHO is investigating the export status of Coldrif.
- Coldrif has been linked to the deaths of over 20 children.
- Diethylene glycol found in Coldrif poses serious health risks.
- Several states have banned the sale of Coldrif.
- Parents are advised to be cautious with cough syrups for young children.
New Delhi, Oct 8 (NationPress) In light of rising fatalities among children allegedly linked to contaminated cough syrup, the World Health Organization (WHO) has reached out to Indian officials for clarification concerning the export status of 'Coldrif'.
As reported by Reuters, the WHO is inquiring whether Coldrif has been exported from India.
Upon receiving confirmation from Indian health authorities, the global health organization indicated it would evaluate the necessity for a Global Medical Products Alert regarding the Coldrif syrup, the report highlighted.
Coldrif, produced by Sresan Pharmaceuticals in Kancheepuram, Tamil Nadu, is associated with the deaths of over 20 children across Madhya Pradesh and Rajasthan.
On October 2, drug control authorities in Tamil Nadu revealed that the sample of Coldrif syrup they analyzed was found to be adulterated. The sample contained a high concentration of diethylene glycol (48.6% w/v), a hazardous substance that may pose serious health risks, as stated in the report.
Multiple states, including Tamil Nadu, Kerala, Madhya Pradesh, Punjab, and Arunachal Pradesh, have prohibited the sale of Coldrif. Additionally, states like Telangana, Karnataka, and Maharashtra have issued alerts regarding its use.
Officials from the Health Ministry mentioned that the CDSCO has already advocated for the cancellation of the license belonging to the problematic manufacturer, although the final decision rests with the Tamil Nadu FDA.
Diethylene Glycol (DEG) is a toxic compound that has been linked to kidney damage.
CDSCO inspections revealed unaccounted containers of DEG at the Sresan Pharma facility, where it was reported that the company was incorporating 46-48% of DEG into the cough syrup, far exceeding the permissible limit of 0.1%.
Meanwhile, the Director General of Health Services, Dr. Sunita Sharma, issued an advisory to all states and union territories, encouraging the prudent use of cough syrups among pediatric populations.
"Cough and cold medications should not be prescribed or dispensed to children under 2 years," she emphasized.
In specific circumstances, it should only be administered after thorough clinical assessment, with strict adherence to appropriate dosing, the shortest effective period, and avoidance of multiple drug combinations.
Point of View
It is imperative we prioritize public safety and health. The rising fatalities among children attributed to contaminated cough syrup demand immediate attention from both authorities and manufacturers. This situation underscores the necessity for stringent regulations and oversight in the pharmaceutical industry to protect our most vulnerable populations.
NationPress
10/10/2025
Frequently Asked Questions
What is Coldrif?
Coldrif is a cough syrup manufactured by Sresan Pharmaceuticals and has been linked to several child fatalities due to contamination.
What is the concern related to Coldrif?
The concern involves contamination with diethylene glycol, a toxic substance, which has been found in high concentrations in Coldrif syrup.
What actions have been taken against Coldrif?
Several states have banned the sale of Coldrif, and the CDSCO has recommended the cancellation of the drug maker's license.
What should parents know about cough syrups for children?
Parents should avoid giving cough and cold medications to children under 2 years unless advised by a healthcare provider.
How is the government responding to this situation?
The government is investigating the matter and has issued advisories to ensure the safe use of cough syrups in pediatric care.
